TR200504220T2 - Aktif limfotoksin-beta reseptör imunoglobülin şimeAktif limfotoksin-beta reseptör imunoglobülin şimerik proteinlerinin yüksek düzey ifadesi ve saflaştrik proteinlerinin yüksek düzey ifadesi ve saflaştırılması için bir yöntem.ırılması için bir yöntem. - Google Patents

Aktif limfotoksin-beta reseptör imunoglobülin şimeAktif limfotoksin-beta reseptör imunoglobülin şimerik proteinlerinin yüksek düzey ifadesi ve saflaştrik proteinlerinin yüksek düzey ifadesi ve saflaştırılması için bir yöntem.ırılması için bir yöntem.

Info

Publication number
TR200504220T2
TR200504220T2 TR2005/042202005/04220T TR200504220T TR200504220T2 TR 200504220 T2 TR200504220 T2 TR 200504220T2 TR 200504220 T TR200504220 T TR 200504220T TR 200504220 T2 TR200504220 T2 TR 200504220T2
Authority
TR
Turkey
Prior art keywords
purification
beta receptor
receptor immunoglobulin
proteins
active lymphotoxin
Prior art date
Application number
TR2005/042202005/04220T
Other languages
English (en)
Inventor
Browning Jeffrey
Miatkowski Konrad
Meier Werner
Original Assignee
Biogen Idec Ma Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22345666&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TR200504220(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Biogen Idec Ma Inc. filed Critical Biogen Idec Ma Inc.
Publication of TR200504220T2 publication Critical patent/TR200504220T2/tr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7151—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Abstract

Aktif limfotoksin-beta reseptör imunoglobülin şimeAktif limfotoksin-beta reseptör imunoglobülin şimerik proteinlerinin yüksek düzey ifadesi ve saflaştrik proteinlerinin yüksek düzey ifadesi ve saflaştırılması için yöntemler.ırılması için yöntemler.
TR2005/042202005/04220T 1998-12-17 1999-11-16 Aktif limfotoksin-beta reseptör imunoglobülin şimeAktif limfotoksin-beta reseptör imunoglobülin şimerik proteinlerinin yüksek düzey ifadesi ve saflaştrik proteinlerinin yüksek düzey ifadesi ve saflaştırılması için bir yöntem.ırılması için bir yöntem. TR200504220T2 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US11275298P 1998-12-17 1998-12-17

Publications (1)

Publication Number Publication Date
TR200504220T2 true TR200504220T2 (tr) 2007-04-24

Family

ID=22345666

Family Applications (2)

Application Number Title Priority Date Filing Date
TR2005/042202005/04220T TR200504220T2 (tr) 1998-12-17 1999-11-16 Aktif limfotoksin-beta reseptör imunoglobülin şimeAktif limfotoksin-beta reseptör imunoglobülin şimerik proteinlerinin yüksek düzey ifadesi ve saflaştrik proteinlerinin yüksek düzey ifadesi ve saflaştırılması için bir yöntem.ırılması için bir yöntem.
TR2001/01703T TR200101703T2 (tr) 1998-12-17 1999-12-16 Aktif limfotoksin-ß reseptör imunoglobülin şimerik proteinlerinin yüksek düzey ifadesi ve saflaştırılması için bir yöntem.

Family Applications After (1)

Application Number Title Priority Date Filing Date
TR2001/01703T TR200101703T2 (tr) 1998-12-17 1999-12-16 Aktif limfotoksin-ß reseptör imunoglobülin şimerik proteinlerinin yüksek düzey ifadesi ve saflaştırılması için bir yöntem.

Country Status (27)

Country Link
US (3) US7585946B2 (tr)
EP (3) EP3006563A1 (tr)
JP (4) JP4878676B2 (tr)
KR (3) KR20070091227A (tr)
CN (2) CN100387708C (tr)
AT (1) ATE536372T1 (tr)
AU (2) AU777232B2 (tr)
BR (1) BR9916325B1 (tr)
CA (1) CA2354539A1 (tr)
CY (1) CY1117003T1 (tr)
CZ (1) CZ20012156A3 (tr)
DK (2) DK2374872T4 (tr)
EA (1) EA005270B1 (tr)
EE (1) EE200100324A (tr)
ES (1) ES2554482T5 (tr)
HK (2) HK1038244A1 (tr)
HU (1) HUP0200064A2 (tr)
IL (3) IL143670A0 (tr)
IS (1) IS5959A (tr)
NO (1) NO20012991L (tr)
NZ (3) NZ529276A (tr)
PT (1) PT2374872E (tr)
SG (1) SG123531A1 (tr)
SI (1) SI2374872T2 (tr)
SK (1) SK8552001A3 (tr)
TR (2) TR200504220T2 (tr)
WO (1) WO2000036092A2 (tr)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5925351A (en) * 1995-07-21 1999-07-20 Biogen, Inc. Soluble lymphotoxin-β receptors and anti-lymphotoxin receptor and ligand antibodies as therapeutic agents for the treatment of immunological disease
US7060667B1 (en) * 1998-01-30 2006-06-13 Biogen Idec Ma, Inc. Treatment of follicular lymphomas using inhibitors of the LT pathway
DE69931944T2 (de) * 1998-10-09 2007-02-08 Biogen Idec Ma Inc., Cambridge Umkehr des viral-induzierten systemischen schocks und des atemnotsyndroms durch blockierung des lymphotoxin-beta- aktivierungsweges
US7951378B2 (en) 2000-04-28 2011-05-31 Planet Biotechnology Inc. Immunoadhesin comprising a chimeric ICAM-1 molecule produced in a plant
US20020168367A1 (en) * 2000-04-28 2002-11-14 Planet Biotechnology Incorporated Novel immunoadhesins for treating and preventing viral and bacterial diseases
DE60211329T2 (de) * 2001-01-16 2007-05-24 Regeneron Pharmaceuticals, Inc. Isolierung von sezernierte proteine exprimierenden zellen
US20090137416A1 (en) 2001-01-16 2009-05-28 Regeneron Pharmaceuticals, Inc. Isolating Cells Expressing Secreted Proteins
CA2511013A1 (en) * 2002-12-20 2004-07-15 Biogen Idec Ma Inc. Multivalent lymphotoxin beta receptor agonists and therapeutic uses thereof
WO2004058944A2 (en) 2002-12-23 2004-07-15 Bristol-Myers Squibb Company Product quality enhancement in mammalian cell culture processes for protein production
MXPA05006523A (es) 2002-12-23 2005-08-26 Squibb Bristol Myers Co Procesos de cultivo de celulas de mamiferos para la produccion de proteinas.
WO2005024012A1 (en) * 2003-09-11 2005-03-17 Novozymes A/S Increased expression of a modified polypeptide
AU2004309114A1 (en) * 2003-12-23 2005-07-14 Laboratoires Serono Sa Process for the production of tumor necrosis factor-binding proteins
WO2007115230A2 (en) * 2006-03-30 2007-10-11 University Of Medicine And Dentistry Of New Jersey A strategy for homo- or hetero-dimerization of various proteins in solutions and in cells
TWI414531B (zh) * 2006-10-12 2013-11-11 Genentech Inc 淋巴毒素α之抗體
JP2010506955A (ja) 2006-10-20 2010-03-04 バイオジェン・アイデック・エムエイ・インコーポレイテッド 可溶性リンホトキシンβレセプターによる脱髄障害の処置
US8338376B2 (en) * 2006-10-20 2012-12-25 Biogen Idec Ma Inc. Compositions comprising variant LT-B-R-IG fusion proteins
CA2680792A1 (en) * 2007-03-15 2008-09-18 Biogen Idec Ma Inc. Treatment of autoimmune disorders
TW200902708A (en) 2007-04-23 2009-01-16 Wyeth Corp Methods of protein production using anti-senescence compounds
EP2615112A3 (en) * 2008-02-29 2013-08-21 Biogen Idec MA Inc. Purified immunoglobulin fusion proteins and methods of their purification
US9540426B2 (en) 2009-10-06 2017-01-10 Bristol-Myers Squibb Company Mammalian cell culture processes for protein production
WO2011134919A2 (en) 2010-04-26 2011-11-03 Novartis Ag Improved cell cultivation process
WO2012176158A1 (en) * 2011-06-24 2012-12-27 Dr. Reddy's Laboratories Limited Purification of chimeric protein
US9279014B2 (en) * 2011-08-17 2016-03-08 Ares Trading S.A. Methods for preparing an active TNFR-Fc fusion protein
EP2906683B1 (en) 2012-10-15 2017-05-31 Bristol-Myers Squibb Company Mammalian cell culture processes for protein production
TW202206465A (zh) 2012-11-14 2022-02-16 美商再生元醫藥公司 重組細胞表面捕捉蛋白質
CA2990885A1 (en) 2015-06-30 2017-01-05 Sanford-Burnham Medical Research Institute Btla fusion protein agonists and uses thereof
KR101936049B1 (ko) 2015-10-15 2019-01-08 (주)알테오젠 IgG Fc 도메인을 가지는 융합 단백질의 생산방법
CN105400721A (zh) * 2015-12-11 2016-03-16 湖南农业大学 一种快速筛选具有抗菌活性芽孢杆菌的方法

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2906096A (en) 1953-12-14 1959-09-29 Pacific Ind Mfg Co Precision control system for press brakes or the like
EP0480923B1 (en) † 1989-07-04 1993-09-29 Novo Nordisk A/S Method of producing proteins with fviii activity and/or fviii derivatives
US5605690A (en) * 1989-09-05 1997-02-25 Immunex Corporation Methods of lowering active TNF-α levels in mammals using tumor necrosis factor receptor
AU8228891A (en) 1990-06-27 1992-01-23 Biogen, Inc. Surface complexed lymphotoxin
US5670149A (en) 1990-06-27 1997-09-23 Biogen, Inc. Lymphotoxin-β, Lymphotoxin-β complexes, pharmaceutical preparations and therapeutic uses thereof
US7030080B2 (en) 1990-06-27 2006-04-18 Biogen, Inc. Lymphotoxin-β, lymphotoxin-β complexes, pharmaceutical preparations and therapeutic uses thereof
DK0585287T3 (da) † 1990-07-10 2000-04-17 Cambridge Antibody Tech Fremgangsmåde til fremstilling af specifikke bindingsparelementer
NZ240718A (en) * 1990-11-30 1996-10-28 Bio Technology General Corp Somatotropin analogues carrying mutations in the alpha-helix-1 region
US5656272A (en) * 1991-03-18 1997-08-12 New York University Medical Center Methods of treating TNF-α-mediated Crohn's disease using chimeric anti-TNF antibodies
MX9204374A (es) * 1991-07-25 1993-03-01 Idec Pharma Corp Anticuerpo recombinante y metodo para su produccion.
US5447851B1 (en) * 1992-04-02 1999-07-06 Univ Texas System Board Of Dna encoding a chimeric polypeptide comprising the extracellular domain of tnf receptor fused to igg vectors and host cells
AU4382193A (en) * 1992-05-19 1993-12-13 Xoma Corporation BPI-immunoglobulin fusion proteins
CA2123593C (en) * 1992-09-15 2000-03-14 Craig A. Smith Method of treating tnf-dependent inflammation using tumor necrosis factor antagonists
WO1994006478A1 (en) 1992-09-22 1994-03-31 Medin Corporation A system for securing medical tools for sterilization
US5837242A (en) † 1992-12-04 1998-11-17 Medical Research Council Multivalent and multispecific binding proteins, their manufacture and use
US5691196A (en) * 1992-12-31 1997-11-25 American Cyanamid Company Recombinant nucleic acid containing a response element
US5429746A (en) 1994-02-22 1995-07-04 Smith Kline Beecham Corporation Antibody purification
US5856179A (en) 1994-03-10 1999-01-05 Genentech, Inc. Polypeptide production in animal cell culture
US5726039A (en) 1994-07-21 1998-03-10 Yissum Research Development Co. Of The Hebrew University Of Jerusalem Vectors and transformed host cells for recombinant protein production at reduced temperatures
US5541087A (en) 1994-09-14 1996-07-30 Fuji Immunopharmaceuticals Corporation Expression and export technology of proteins as immunofusins
US6312691B1 (en) 1996-01-26 2001-11-06 Jeffrey L. Browning Lymphotoxin-α/β complexes and anti-lympotoxin-β receptor antibodies as anti-tumor agents
US5705364A (en) 1995-06-06 1998-01-06 Genentech, Inc. Mammalian cell culture process
US5721121A (en) 1995-06-06 1998-02-24 Genentech, Inc. Mammalian cell culture process for producing a tumor necrosis factor receptor immunoglobulin chimeric protein
US5925351A (en) 1995-07-21 1999-07-20 Biogen, Inc. Soluble lymphotoxin-β receptors and anti-lymphotoxin receptor and ligand antibodies as therapeutic agents for the treatment of immunological disease
US6291207B1 (en) * 1995-07-28 2001-09-18 Northwestern University Herpes virus entry receptor protein
JP4306813B2 (ja) † 1995-09-19 2009-08-05 アスビオファーマ株式会社 動物細胞の新規培養方法
CA2253557A1 (en) * 1996-05-08 1997-11-13 Louis Martin Renzetti Treatment of asthma with tnfr-ig
US6040560A (en) * 1996-10-22 2000-03-21 Philip Morris Incorporated Power controller and method of operating an electrical smoking system
US7255854B1 (en) 1996-10-25 2007-08-14 Biogen, Inc. Use of lymphotoxin-β receptor blocking agents for the treatment of antibody mediated immunological diseases
KR100584704B1 (ko) * 1996-10-25 2006-05-30 바이오겐 아이덱 엠에이 인코포레이티드 면역 질환을 치료하기 위한 치료제로서의 가용성 림포톡신-베타 수용체, 항림포톡신 수용체 항체 및 항림포톡신 리간드 항체
CA2270913C (en) 1996-10-30 2011-05-24 Human Genome Sciences, Inc. Human tumor necrosis factor receptor-like 2
CA2272822A1 (en) * 1996-12-12 1998-06-18 Genentech, Inc. Hvem polypeptides and uses thereof
US6221608B1 (en) * 1997-01-22 2001-04-24 Ortho Pharmaceutical Corporation Methods for identifying erythropoietin receptor binding protein
US7060667B1 (en) 1998-01-30 2006-06-13 Biogen Idec Ma, Inc. Treatment of follicular lymphomas using inhibitors of the LT pathway
US6693181B2 (en) * 1998-04-16 2004-02-17 Genentech, Inc. Protein secretion
DE69929198T2 (de) † 1998-05-29 2006-08-10 Genentech, Inc., South San Francisco Zellkulturverfahren für die produktion von glycoproteinen
DE69931944T2 (de) 1998-10-09 2007-02-08 Biogen Idec Ma Inc., Cambridge Umkehr des viral-induzierten systemischen schocks und des atemnotsyndroms durch blockierung des lymphotoxin-beta- aktivierungsweges
US7294481B1 (en) 1999-01-05 2007-11-13 Immunex Corporation Method for producing recombinant proteins
US9086881B2 (en) 2012-06-29 2015-07-21 Intel Corporation Mechanism for facilitating write tracking for following data eye movements across changing thermal conditions in memory systems

Also Published As

Publication number Publication date
TR200101703T2 (tr) 2002-05-21
US20100136625A1 (en) 2010-06-03
KR20070091227A (ko) 2007-09-07
PT2374872E (pt) 2015-12-09
US8283138B2 (en) 2012-10-09
HK1038244A1 (en) 2002-03-08
JP4878676B2 (ja) 2012-02-15
PL348816A1 (en) 2002-06-17
WO2000036092A3 (en) 2000-11-23
CA2354539A1 (en) 2000-06-22
NZ538599A (en) 2007-11-30
EA005270B1 (ru) 2004-12-30
ES2554482T3 (es) 2015-12-21
JP5777171B2 (ja) 2015-09-09
NZ549623A (en) 2008-05-30
SG123531A1 (en) 2006-07-26
WO2000036092A2 (en) 2000-06-22
CY1117003T1 (el) 2017-04-05
CN101289512A (zh) 2008-10-22
JP2013116118A (ja) 2013-06-13
US20020039580A1 (en) 2002-04-04
JP2014239697A (ja) 2014-12-25
CN1333819A (zh) 2002-01-30
CZ20012156A3 (cs) 2001-09-12
NZ529276A (en) 2005-03-24
EP2374872B2 (en) 2019-02-20
HK1223398A1 (zh) 2017-07-28
US20130196376A1 (en) 2013-08-01
CN100387708C (zh) 2008-05-14
KR20060084860A (ko) 2006-07-25
NO20012991D0 (no) 2001-06-15
DK1141248T3 (da) 2012-03-12
AU2005200042B2 (en) 2008-05-01
EP1141248A2 (en) 2001-10-10
WO2000036092A9 (en) 2002-08-22
DK2374872T4 (en) 2019-04-23
EE200100324A (et) 2002-10-15
ATE536372T1 (de) 2011-12-15
AU777232B2 (en) 2004-10-07
EP2374872A2 (en) 2011-10-12
IL143670A0 (en) 2002-04-21
US7585946B2 (en) 2009-09-08
NO20012991L (no) 2001-08-17
SI2374872T1 (sl) 2016-03-31
US8709759B2 (en) 2014-04-29
EP2374872B1 (en) 2015-11-25
IL229738A0 (en) 2014-01-30
EP1141248B1 (en) 2011-12-07
ES2554482T5 (es) 2019-07-18
AU2364400A (en) 2000-07-03
KR20020013482A (ko) 2002-02-20
EP2374872A3 (en) 2011-10-19
AU2005200042A1 (en) 2005-02-03
IL205698A (en) 2015-11-30
SI2374872T2 (sl) 2019-05-31
IS5959A (is) 2001-05-31
SK8552001A3 (en) 2001-12-03
JP2010158252A (ja) 2010-07-22
EP3006563A1 (en) 2016-04-13
EA200100670A1 (ru) 2001-12-24
JP2003517277A (ja) 2003-05-27
HUP0200064A2 (en) 2002-05-29
DK2374872T3 (en) 2015-12-14
BR9916325B1 (pt) 2011-06-28
KR100732934B1 (ko) 2007-06-29
BR9916325A (pt) 2001-10-02

Similar Documents

Publication Publication Date Title
TR200504220T2 (tr) Aktif limfotoksin-beta reseptör imunoglobülin şimeAktif limfotoksin-beta reseptör imunoglobülin şimerik proteinlerinin yüksek düzey ifadesi ve saflaştrik proteinlerinin yüksek düzey ifadesi ve saflaştırılması için bir yöntem.ırılması için bir yöntem.
DE69838061D1 (de) Typ ii tgf-beta receptor/immunoglobulin konstante domäne fusionsproteine
IS5547A (is) Forlyf fyrir tálma við aspartílprótínkljúfum
DE69930424D1 (de) Anti-HER2 Antikörperzusammensetzung
PT939767E (pt) Factor viii porcino e seus hibridos
DE69735295D1 (de) Verfahren zur Aufkonzentrierung von Antikörperlösungen
NO974213L (no) Små-molekylære inhibitorer for rotamase-enzym-aktivitet
KR950700779A (ko) 단백질의 정제방법(Protein purification)
ATE278785T1 (de) Neues verfahren zur gewinnung und reinigung von fusionsproteinen
DE69903410D1 (de) Entkarbonisierung von gasen unter verwendung von zeolithischen adsorptionsmitteln
NO993424D0 (no) Fremgangsmåte til selektiv nedbrytning av melkeprotein i naervaer av andre melkeproteiner
DE69828154D1 (de) Anti-alphavbeta3 humanizierte monoklonale antikörper
DK0763100T3 (da) Fremgangsmåde til rensning af Clostridium difficile-texin og fremstilling af monospecifkke antistoffer
DE69823225D1 (de) Fusionsproteine, bestehend aus proteinaseinhibitoren
ATE294237T1 (de) S?ugetier thymokingene
ATE307201T1 (de) Srcr domäne-enthaltendes protein
ATE33842T1 (de) Immuninterferon und verfahren zu seiner reinigung.
SE8305409L (sv) Brennare for biobrenslen
UA26876C2 (uk) Спосіб очистки відхідhих газів
SE8306548L (sv) Nackstod for fordonsstolar
KR970038899U (ko) 아이빔 운반지그의 구조
AR002059A1 (es) Procedimiento para aislar y purificar una proteina de plasma humano con actividad fibrinolitica
FI973295A (fi) Menetelmä lentotuhkan tiivistämiseksi
IT1277669B1 (it) Metodo di misura di concentrazione di portatori